文献速递放射性药物与辐射防护

COVID-19肺炎:全身FDG PET/CT评估的炎症与短期临床结局的关系

COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-07-25

该前瞻性研究纳入13例因COVID-19住院的非危重患者,在症状出现后第6至14天行FDG PET/CT,按表现分为「炎症型」或「低炎症型」,并与胸部CT演变和短期临床结局比较。结果显示肺部最大标准化摄取值范围为4.7至16.3,所有患者纵隔淋巴结葡萄糖摄取增高,但PET肺部炎症状态与胸部CT演变或短期临床结局无相关性。

要点

  • COVID-19炎症高峰期FDG PET/CT显示肺部葡萄糖摄取不均匀,最大标准化摄取值4.7至16.3。
  • 所有13例患者均见纵隔淋巴结葡萄糖摄取增高,部分见鼻咽、骨髓、脾脏轻度增高。
  • PET肺部炎症状态与胸部CT演变及短期临床结局无相关性。

核心结论

  • COVID-19患者在推测的炎症高峰期,FDG PET/CT扫描可见明显的炎症过程,葡萄糖摄取不均匀且典型集中于肺部。

研究设计与样本

  • 前瞻性研究,纳入13例因COVID-19住院的非危重患者,在症状出现后第6至14天行FDG PET/CT,按表现分为「炎症型」或「低炎症型」,并与胸部CT演变和短期临床结局比较。
  • 试验注册号NCT04441489,于2020年6月22日回顾性注册。

主要发现

  • 肺部最大标准化摄取值范围为4.7至16.3。
  • 所有患者均显示纵隔淋巴结葡萄糖摄取增高。
  • 3例(23%)患者鼻咽部轻度葡萄糖摄取增高,2例(15%)骨髓轻度增高,5例(38%)脾脏轻度增高。
  • 无患者出现显著的消化道局灶性或节段性葡萄糖摄取。
  • 除1例外,所有患者均无显著生理性心肌葡萄糖摄取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. METHODS: Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients' profiles were classified as "inflammatory" or "low inflammatory." FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism. RESULTS: Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome. CONCLUSION: Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs. TRIAL REGISTRATION: NCT04441489. Registered 22 June 2020 (retrospectively registered).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Dietz M, Chironi G, Claessens YE, et al. COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome. Eur J Nucl Med Mol Imaging. 2020. PMID: 32712702. doi:10.1007/s00259-020-04968-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。